Daiichi’s Savaysa goes up against next-gen anticoagulant trio in heated market race

Carly Helfand

What's long been a three-horse just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter . With the FDA's Thursday blessing, the drug will now face down a new-age trifecta that's been duking it out in the marketplace for a while now.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS